8-K: Provectus Biopharma Inks Exclusive License Deal with University of Miami for Eye Infection Treatment

Provectus Biopharmaceuticals has secured an exclusive worldwide license from the University of Miami to develop a photodynamic antimicrobial therapy for eye infections.

Summary

• Provectus Biopharmaceuticals has entered into an exclusive license agreement with the University of Miami to develop and commercialize a photodynamic antimicrobial therapy (PDAT) for treating various eye infections.
• The agreement grants Provectus worldwide rights to the University's intellectual property related to PDAT in ophthalmology.
• Provectus will pay an upfront fee of $10,000, royalties of 10% on net sales, and annual payments starting at $1,000 and increasing to $10,000 after four years.
• In the event of a sublicense, Provectus will pay the University royalties ranging from 10% to 30% of sublicense income, depending on the clinical trial phase.
• Provectus is required to form a new corporation (NewCo) within one year to develop and commercialize the licensed products, assigning the license to NewCo and issuing 5% of NewCo's shares to the University.
• The University will have anti-dilution rights until NewCo raises $2,000,000 in cash.
• The agreement includes development milestones, such as creating a product suitable for FDA submission, generating necessary data, submitting a drug-device application, and receiving FDA approval.
• Milestone payments include $5,000 upon the first commercial sale and $50,000 upon reaching $500,000 in net sales.
• The license term extends until the expiration of all related patents, regulatory exclusivity, or 20 years from the first commercial sale, whichever is later.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with a significant licensing agreement, a clear development plan, and a large potential market. The collaboration with a reputable institution and the validation of the technology through prior research contribute to a strong positive sentiment. However, the need for additional funding and the presence of competition temper the optimism slightly.

Positives

• The exclusive worldwide license provides Provectus with a significant opportunity in the ophthalmology market.
• The collaboration with the University of Miami and Bascom Palmer Eye Institute brings credibility and expertise to the project.
• The technology has already been validated through in vitro testing, pilot in vivo safety and clinical studies, and peer-reviewed publications.
• The agreement includes clear milestones and a defined path to commercialization.
• The potential market for treating infectious keratitis is substantial, with an estimated 30,000 to 70,000 patients in the U.S. and several million worldwide.
• The University will receive equity in the new company, aligning their interests with the success of the venture.

Negatives

• Provectus is required to form a new company (NewCo) and assign the license, adding complexity to the project.
• The company must meet specific development milestones within set timeframes, which could be challenging.
• The agreement includes ongoing financial obligations, including royalties and annual payments.
• The company will need to raise additional capital to fund the development and commercialization of the technology, with an estimated $7,500,000 to $10,000,000 required.
• The company faces competition from existing treatments, such as riboflavin-based PDAT.

Risks

• The development of the licensed product is subject to regulatory approvals, which may be delayed or denied.
• The company may face challenges in meeting the required development milestones within the specified timeframes.
• The commercial success of the product depends on market acceptance and competition from existing treatments.
• The company will need to secure additional funding to support the development and commercialization efforts.
• There is a risk of intellectual property infringement or challenges to the validity of the licensed patents.

Future Outlook

Provectus plans to form a new company to develop and commercialize the licensed technology, with the goal of reducing or eliminating the risk of blindness and impaired vision from eye infections worldwide. The company anticipates a product launch within 36 months of securing funding.

Management Comments

• Dr. Parel stated that the rose bengal PDAT is the result of hard work by a cross-disciplinary team and they look forward to working with Provectus to deliver the treatment to patients worldwide.
• Dr. Amescua noted that the innovation is needed globally as infectious keratitis is a leading cause of corneal blindness.
• Ed Pershing, Chairman of Provectus' Board of Directors, expressed pleasure in continuing the collaboration and highlighted the potential impact of the medical innovation.

Industry Context

This announcement aligns with the growing interest in photodynamic therapy for treating infections and the increasing focus on addressing unmet needs in ophthalmology. The collaboration between a biotech company and a leading research institution like the University of Miami is a common approach to advancing innovative medical technologies.

Comparison to Industry Standards

• The agreement is similar to other licensing deals between universities and biotech companies, where the university provides intellectual property and the company provides the resources for development and commercialization.
• The royalty rates of 10% on net sales and 10-30% on sublicense income are within the typical range for such agreements.
• The development milestones and timelines are consistent with the regulatory pathway for medical devices and pharmaceuticals.
• The competitive landscape includes companies like Glaukos, which is developing a riboflavin-based PDAT, indicating a growing market for this type of treatment.
• The Bascom Palmer Eye Institute is a leading eye care center, which adds credibility to the technology being licensed.

Stakeholder Impact

• Shareholders: The agreement is expected to positively impact the company's value and future prospects.
• Employees: The agreement may lead to new job opportunities and growth within the company.
• Customers: The development of the licensed product could provide a new treatment option for eye infections.
• Suppliers: The company may require new suppliers for the development and manufacturing of the product.
• Creditors: The company may need to secure additional financing to support the development plan.

Next Steps

• Provectus will form a new corporation (NewCo) to develop and commercialize the licensed products.
• The company will assign the license agreement to NewCo.
• Provectus will execute an equity agreement with the University of Miami.
• NewCo will develop a product suitable for FDA submission.
• NewCo will generate data suitable for FDA submission.
• NewCo will submit a drug-device combination application to the FDA.
• NewCo will seek FDA clearance, approval, or authorization for the licensed product.
• Provectus will raise $7,500,000 to $10,000,000 to fund the development plan.

Key Dates

Keywords

photodynamic antimicrobial therapy, ophthalmology, rose bengal sodium, eye infections, keratitis, exclusive license, medical device, drug development, University of Miami, Bascom Palmer Eye Institute